Phase II Safety and Efficacy Study to Evaluate a Glaucoma... | NCT00069706 | Trialant

Phase II Safety and Efficacy Study to Evaluate a Glaucoma... | NCT00069706 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
AL-12182 0.003%	Experimental	One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days	Drug: AL-12182 0.003% Ophthalmic Solution
AL-12182 Solution Vehicle	Placebo Comparator	One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days	Other: AL-12182 Ophthalmic Solution Vehicle
Latanoprost	Active Comparator	One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days	Drug: Latanoprost 0.005% Ophthalmic Solution
AL-12182 0.01%	Experimental	One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days	Drug: AL-12182 0.01% Ophthalmic Solution
AL-12182 0.03%	Experimental	One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days	Drug: AL-12182 0.03% Ophthalmic Solution

Interventions

Name	Type	Description	Arm Group Labels	Other Names
AL-12182 0.003% Ophthalmic Solution	Drug	Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension	AL-12182 0.003%

Ancestor Terms

ID	Term
D019999	Pharmaceutical Solutions
D012996	Solutions
D004364	Pharmaceutical Preparations
D045506	Therapeutic Uses
D020228	Pharmacologic Actions
D020164	Chemical Actions and Uses
D020313	Specialty Uses of Chemicals
D011461	Prostaglandins F, Synthetic
D011465	Prostaglandins, Synthetic
D011453	Prostaglandins
D015777	Eicosanoids
D005231	Fatty Acids, Unsaturated
D005227	Fatty Acids
D008055	Lipids
D012898	Autacoids
D018836	Inflammation Mediators
D001685	Biological Factors